The Science Behind Immune Support Supplements

Therapeutic dose: 1,000–4,000 IU/day (25–100 mcg); higher doses to correct deficiency

See ranked Vitamin D products→

• Martineau et al. (2017) meta-analysis of 25 RCTs (11,321 participants) found vitamin D supplementation reduced risk of acute respiratory tract infection by 12% overall, and by 70% in those with severe deficiency (<10 ng/mL).PubMed ↗
• 2020 update of the same meta-analysis (46 RCTs, 75,541 participants) confirmed the protective effect against acute respiratory infections. Daily or weekly dosing was effective; large bolus doses were not.PubMed ↗
• Vitamin D activates innate immune defenses: upregulates cathelicidin and defensins (antimicrobial peptides), enhances macrophage killing of pathogens, and modulates T-cell response to reduce excessive inflammation.
• Deficiency (~42% of US adults) is a clear risk factor. Supplementation corrects immune dysfunction in deficient individuals, but there is limited evidence for benefit in replete individuals. Test and correct deficiency first.

Therapeutic dose: 15–30 mg/day (maintenance); 75 mg/day zinc acetate lozenges (acute cold treatment)

See ranked Zinc products→

• Cochrane review (2013, updated 2023, 18 RCTs) found zinc lozenges (≥75 mg/day, started within 24h of symptoms) reduced common cold duration by 33%. Zinc acetate lozenges were more effective than zinc gluconate.PubMed ↗
• 2021 meta-analysis of 28 RCTs found zinc supplementation reduced incidence of acute respiratory infections by 28% in children and adults. Preventive dosing (15–30 mg/day) reduced cold incidence; therapeutic dosing shortened duration.PubMed ↗
• Zinc is required for development and function of neutrophils, NK cells, and T-cells. Even mild deficiency impairs immune response. Groups at risk: elderly, vegetarians, those with GI disorders.
• Long-term supplementation above 40 mg/day can cause copper deficiency. Zinc nasal sprays were linked to permanent anosmia (loss of smell) and should be avoided. Oral lozenges or capsules are the studied forms.

Therapeutic dose: 200–1,000 mg/day (preventive); 1,000–2,000 mg/day (acute treatment)

See ranked Vitamin C products→

• Hemila & Chalker Cochrane review (2013, 29 RCTs, 11,306 participants) found regular vitamin C supplementation (≥200 mg/day) reduced cold duration by 8% in adults and 14% in children. Did NOT reduce cold incidence in the general population.PubMed ↗
• In 5 trials of participants under extreme physical stress (marathon runners, soldiers, skiers), vitamin C reduced cold incidence by 52%. Benefit appears greatest in populations with elevated oxidative stress.
• Therapeutic vitamin C (started after cold onset) showed inconsistent results in 7 trials — modest benefit at ≥1g/day but the evidence is weaker than for preventive use.
• Vitamin C accumulates in immune cells (neutrophils, lymphocytes) at 10–100x plasma concentrations. Supports epithelial barrier function, phagocyte killing, and lymphocyte proliferation. Rapidly depleted during infection.
• Mega-dosing (>2g/day) offers no additional benefit and increases GI side effects and kidney stone risk. Plasma levels saturate at ~200 mg/day oral intake.

Therapeutic dose: 1–10 billion CFU/day (strain-dependent)

See ranked Probiotics products→

• 2015 Cochrane review of 12 RCTs found probiotics reduced incidence of upper respiratory infections and mean episode duration, with a moderate quality of evidence.PubMed ↗
• 2022 meta-analysis of 23 RCTs found probiotics reduced respiratory infection incidence by 26% and antibiotic use by 29% in adults. Lactobacillus and Bifidobacterium strains were most studied.PubMed ↗
• Effects are highly strain-specific. Lactobacillus rhamnosus GG and Lactobacillus paracasei have the most evidence. Generic 'probiotic' claims without specifying strains are unreliable.
• Mechanism: probiotics modulate gut-associated lymphoid tissue (GALT), which contains ~70% of the immune system. They enhance IgA secretion, regulate T-cell differentiation, and strengthen mucosal barriers.

Therapeutic dose: 55–200 mcg/day (as selenomethionine or selenium yeast)

See ranked Selenium products→

• 2019 systematic review found selenium supplementation enhanced immune cell function (NK cell activity, T-cell proliferation) and improved response to vaccination, primarily in selenium-deficient populations.PubMed ↗
• Selenium deficiency is associated with increased virulence of certain viruses — Keshan disease (coxsackievirus B3 cardiomyopathy) is a direct result of selenium deficiency in endemic areas of China.
• Selenoproteins (glutathione peroxidases, thioredoxin reductases) are critical for antioxidant defense in immune cells. Low selenium status is associated with poorer outcomes in viral infections including HIV.
• Caution: narrow therapeutic window. Toxicity (selenosis) can occur at >400 mcg/day. Brazil nuts contain highly variable selenium — 1 nut can provide 10–90 mcg.

Therapeutic dose: 250–500 mg/day (yeast-derived beta-1,3/1,6-glucan)

See ranked Beta-Glucan (1,3/1,6) products→

• 2019 meta-analysis of 8 RCTs found beta-glucan supplementation reduced upper respiratory infection incidence by 25% and symptom severity in healthy adults.PubMed ↗
• 2013 RCT (162 healthy adults) found 250 mg/day yeast beta-glucan for 90 days reduced cold and flu symptom days by 43% compared to placebo.PubMed ↗
• Mechanism: binds Dectin-1 receptor on macrophages and dendritic cells, activating innate immune response through trained immunity. Primes neutrophils for enhanced pathogen killing without causing inflammation.
• Source matters: yeast-derived (Saccharomyces cerevisiae) beta-1,3/1,6-glucan is most studied. Oat beta-glucan (1,3/1,4) has different immunological properties and is primarily studied for cholesterol.

Therapeutic dose: 600–1,200 mg/day

See ranked N-Acetylcysteine (NAC) products→

• Landmark 1997 RCT (262 elderly adults) found NAC 600 mg 2x/day for 6 months significantly reduced influenza-like episodes and symptom severity by ~67%, though seroconversion rates were similar — suggesting NAC reduced symptom severity rather than preventing infection.PubMed ↗
• NAC replenishes glutathione — the master intracellular antioxidant that is rapidly depleted during infection. Immune cells require adequate glutathione to maintain function during oxidative burst.
• Also has mucolytic properties (breaks disulfide bonds in mucus glycoproteins) — this is its FDA-approved use. Reduces respiratory mucus viscosity and improves airway clearance during infections.
• Limitation: the key immune RCT is from 1997 and has not been adequately replicated. During COVID-19, several trials were initiated but results were mixed.

Therapeutic dose: 300–600 mg/day extract (standardized to anthocyanins)

See ranked Elderberry (Sambucus nigra) products→

• 2019 meta-analysis of 4 RCTs (180 participants) found elderberry supplementation substantially reduced upper respiratory symptoms. Cold duration was reduced by an average of 2 days, and flu duration by ~4 days.PubMed ↗
• 2004 RCT (60 patients with influenza B) found 15 mL elderberry syrup 4x/day resolved symptoms 4 days earlier than placebo.PubMed ↗
• Mechanism: anthocyanins and flavonoids have direct antiviral activity in vitro (block viral hemagglutinin binding) and immunomodulatory effects (increase cytokine production).
• Limitation: all RCTs are small (n < 100). Theoretical concern about cytokine storm exacerbation in severe infections, though no clinical evidence supports this risk at standard doses.

Therapeutic dose: 100–300 mg/day (bovine lactoferrin)

See ranked Lactoferrin products→

• 2021 systematic review found lactoferrin had broad antimicrobial activity against bacteria, viruses, and fungi in vitro. Human RCTs show reduced incidence of late-onset sepsis in preterm infants, but adult respiratory data is scarce.PubMed ↗
• 2020 RCT (54 participants) found bovine lactoferrin reduced common cold incidence and duration in healthy adults, but the study was small and single-center.
• Mechanism: sequesters iron from pathogens (bacteriostatic), directly disrupts bacterial membranes, and modulates immune cell activity. Most abundant antimicrobial protein in human mucosal secretions.

Therapeutic dose: 700–900 mcg RAE/day (from retinol or beta-carotene)

See ranked Vitamin A products→

• Vitamin A is essential for maintaining mucosal barriers (respiratory, GI, urogenital tract) — the body's first line of immune defense. Deficiency dramatically increases susceptibility to respiratory and diarrheal infections.
• Cochrane review of vitamin A supplementation in children (43 RCTs, 215,633 children) found significant reduction in all-cause mortality and diarrhea incidence — but these were largely in deficient populations in developing countries.PubMed ↗
• In non-deficient adults in developed countries, supplemental vitamin A provides no demonstrated immune benefit and carries toxicity risk. Hypervitaminosis A (>10,000 IU/day long-term) can cause liver damage and is teratogenic.

Therapeutic dose: 1,000–3,000 mg/day (extract standardized to polysaccharides and triterpenes)

See ranked Reishi Mushroom (Ganoderma lucidum) products→

• 2015 Cochrane review of 5 RCTs (373 cancer patients) found reishi enhanced host immune responses (increased CD3+, CD4+, CD8+ T-cells) as an adjunct to conventional treatment, but study quality was very low.PubMed ↗
• In vitro studies show beta-glucans and triterpenes from reishi modulate dendritic cell maturation, macrophage activation, and NK cell cytotoxicity. Translation to clinical immune outcomes is unproven.
• Several reports of hepatotoxicity from reishi extract — including one associated with powdered reishi in a cancer patient. Long-term safety profile is inadequately characterized.

Therapeutic dose: 300–500 mg/day (E. purpurea aerial parts extract)

See ranked Echinacea products→

• Cochrane review (2014, 24 RCTs) found some echinacea products may reduce cold duration and severity, but results were highly inconsistent across trials. No single preparation was reliably effective.PubMed ↗
• 2012 large RCT (719 participants) using E. purpurea found no significant reduction in cold duration or severity compared to placebo.PubMed ↗
• Three species (E. purpurea, E. angustifolia, E. pallida), different plant parts (aerial, root), and extraction methods create enormous variation between products. This heterogeneity makes the evidence base almost impossible to interpret.
• Commercial echinacea products show wild inconsistency in active compound content — one analysis found 0–130% of labeled amounts. Without standardization, clinical trial results are hard to generalize to consumer products.